Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon;Respuesta a largo plazo al interferón y ribavirina en pacientes con hepatitis crónica C sin respuesta sostenida al interferón

Revista Espanola de Enfermedades Digestivas

Volumn 93, Issue 6, 2001, Pages 353-363

  Diago, M ^a   Lujan M ^a   Valeros, D ^a   Tuset, C ^a   Marcaida, G ^a   Garcia V ^a   Cors, R ^a   Carbonell, P ^a  

^a Servicio de Aparato Digestivo   (Spain)

Author keywords

Chronic hepatitis C; Interferon; Ribavirin

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; RELAPSE; TREATMENT OUTCOME; VIREMIA;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT FAILURE;

EID: 0034946785     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Risk factors for acute non A non B hepatitis in the United States and association with hepatitis C virus infection
2. Clinical outcomes after transfussion-associated hepatitis C
3. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus
4. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
5. Therapy of hepatitis C
6. Long term follow-up of patients with chronic hepatitis C treated with a interferon
7. Long term follow up of patients with chronic hepatitis C treated with differen doses of interferon a 2b
8. Ribavirin as therapy for chronic hepatitis C. A randomized, double blind, placebo controlled trial
9. Ribavirin treatment for chronic hepatitis C
10. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis
11. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
12. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha
13. Multinational evaluation of the efficacy and safety of once-weekly peginterferon alfa-2 a in patientes with chronic hepatitis C with compensated cirrhosis
14. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
15. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
16. Is an "À la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C
17. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
18. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
19. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone
20. Combined treatment of relapse of chronic hepatitis C with high-dose a2b interferon plus ribavirin for 6 or 12 months
21. Combination treatment with interferon alfa -2 b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
22. Interferon-ribavirin combination therapy for chronic hepatitis C
23. Combination antiviral therapy with ribavirin and interferon alfa in interferon alpha relapsers and non-responders: Italian experience
24. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
25. EALS International consensus conference of hepatitis C. Consensus estatement
26. Respuesta sostenida con interferón y ribavirina en pacientes con hepatitis crónica C no respondedores a interferón
27. Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: A preliminary study
28. New antiviral agents for viral hepatitis: Our cup runneth over but is only half full